Outcomes and Prognostic Factors for Recurrence After High-Dose Proton Beam Therapy for Centrally and Peripherally Located Stage I Non–Small-Cell Lung Cancer

Kanemoto, Ayae; Okumura, Toshiyuki; Ishikawa, Hitoshi; Mizumoto, Masashi; Oshiro, Yoshiko; Kurishima, Koichi; Homma, Shinsuke; Hashimoto, Takayuki; Ohkawa, A.; Numajiri, Haruko; Ohno, Tomonori; Moritake, Takashi; Tsuboi, Koji; Sakae, Takeji; Sakurai, Hideyuki

doi:10.1016/j.cllc.2013.11.002

Cited by 38 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the LCR for stage I NSCLC, the 85.4% 3-year LCR of our study was comparable to previous SABR series using either photons or protons ( [5,[9][10][11][12][13][14][15]23]; Table 5). The finding that the 3-year LCR of stage IB NSCLC was 65% lower than that of stage IA was also supported by previous reports, ranging from 60 to 80% regardless of photon, proton, or carbon [6,13,15,24].…”

Section: Discussionsupporting

confidence: 77%

“…There has been constant interest in the use of proton beam therapy (PBT) for early-stage lung cancer as well as locally advanced disease [8]. Recently, some investigators have reported a favorable local control rate with acceptable toxicities after ablative dose PBT comparable to those of SABR in early-stage NSCLC patients [9][10][11][12][13][14][15]. However, most PBT studies still have more protracted treatment courses compared with those of SABR standards, so the evidence concerning PBT with hypofractionation for early-stage NSCLC is still limited [9][10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

Lee

Moon²,

Cho

et al. 2016

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

Lee

Moon²,

Cho

et al. 2016

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…In comparison with photons, PBT plans may deliver lower doses to the adjacent organs at risk, such as the esophagus, lungs and bone marrow, thus improving the therapeutic ratio (15). The early clinical outcome of PBT in lung cancer patients (16)(17)(18)(19)(20)(21)(22)(23) demonstrated that proton beam therapy combined with chemotherapy may relatively reduce the rates of toxicity and achieve a possible survival benefit compared with photon beam therapy and 3DCRT (24). Early results (25)(26)(27)(28)(29) suggested that PBT has the advantage of dose escalation, which may prolong patient survival, lower the risk of recurrence and severe toxicity, and intensify chemotherapy (15).…”

Section: Pbt For Different Cancersmentioning

confidence: 99%

The evolution of proton beam therapy: Current and future status (Review)

et al. 2017

View full text Add to dashboard Cite

Abstract. Proton beam therapy (PBT) has been increasingly used in a variety of cancers due to its excellent physical properties and superior dosimetric parameters. PBT may improve patient survival by improving the local tumor treatment rate while reducing injury to normal organs, which may result in fewer radiation-induced adverse effects. However, the significant cost of establishing and maintaining proton facilities cannot be overlooked. In addition, there has been significant controversy regarding routine application of this treatment in certain types of cancer. The challenges of PBT in the future mainly include the lack of basic clinical trials, unclear biological effects, immature imaging technology and miniaturization of imaging guidance. Overcoming these limitations may promote the rapid development of PBT. We herein provide an overview of the existing literature on the efficacy and toxicity of common oncological applications of proton beam therapy.

show abstract

“…In addition, 43.2% of their patients had a simultaneous or sequential occurrence of another cancer (36). They reported 3-year overall survival and local control rates of 76.7 and 81.8%, respectively.…”

Section: Lung Cancermentioning

confidence: 99%

Proton beam therapy in Japan: current and future status

Sakurai

Ishikawa

Okumura

2016

Jpn. J. Clin. Oncol.

Self Cite

View full text Add to dashboard Cite

The number of patients treated by proton beam therapy in Japan since 2000 has increased; in 2016, 11 proton facilities were available to treat patients. Notably, proton beam therapy is very useful for pediatric cancer; since the pediatric radiation dose to normal tissues should be reduced as much as possible because of the effect of radiation on growth, intellectual development, endocrine organ function and secondary cancer development. Hepatocellular carcinoma is common in Asia, and most of the studies of proton beam therapy for liver cancer have been reported by Japanese investigators. Proton beam therapy is also a standard treatment for nasal and paranasal lesions and lesions at the base of the skull, because the radiation dose to critical organs such as the eyes, optic nerves and central nervous system can be reduced with proton beam therapy. For prostate cancer, comparative studies that address adverse effects, safety, patient quality of life and socioeconomic issues should be performed to determine the appropriate use of proton beam therapy for prostate cancer. Regarding new proton beam therapy applications, experience with proton beam therapy combined with chemotherapy is limited, although favorable outcomes have been recently reported for locally advanced lung cancer, esophageal cancer and pancreatic cancer. Therefore, 'chemoproton' therapy appears to be a very attractive field for further clinical investigations. In conclusion, there are cost issues and considerations regarding national insurance for the use of proton beam therapy in Japan. Further studies and discussions are needed to address the use of proton beam therapy for several types of cancers, and for maintaining the quality of life of patients while retaining a high cure rate.

show abstract

Outcomes and Prognostic Factors for Recurrence After High-Dose Proton Beam Therapy for Centrally and Peripherally Located Stage I Non–Small-Cell Lung Cancer

Cited by 38 publications

References 31 publications

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas

The evolution of proton beam therapy: Current and future status (Review)

Proton beam therapy in Japan: current and future status

Contact Info

Product

Resources

About